Takeda Pharma Files 6-K, Reports as Foreign Issuer
Ticker: TKPHF · Form: 6-K · Filed: Nov 28, 2025 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Nov 28, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, sec-filing, foreign-private-issuer
TL;DR
Takeda filed a 6-K on Nov 28, 2025, confirming 20-F annual report filings.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on November 28, 2025, reporting as a foreign private issuer. The filing indicates Takeda will file its annual reports under Form 20-F. The company's principal executive offices are located in Tokyo, Japan.
Why It Matters
This filing confirms Takeda's reporting status and adherence to SEC regulations for foreign private issuers, providing transparency for investors.
Risk Assessment
Risk Level: low — This is a routine administrative filing confirming reporting status and not disclosing new material financial or operational information.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Filer
- 001-38757 (company) — SEC File Number
- 20-F (document) — Annual Report Form
- 6-K (document) — Filing Form
- November 2025 (date) — Reporting Period
- November 28, 2025 (date) — Filing Date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report as a foreign private issuer and confirm that Takeda Pharmaceutical Company Limited files its annual reports under Form 20-F.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on November 28, 2025.
What is Takeda Pharmaceutical Company Limited's SEC file number?
Takeda Pharmaceutical Company Limited's SEC file number is 001-38757.
Where are Takeda's principal executive offices located?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, 103-8668, Japan.
Does Takeda file its annual reports as Form 20-F or Form 40-F?
Takeda indicates it files its annual reports under Form 20-F.
Filing Stats: 193 words · 1 min read · ~1 pages · Grade level 15.2 · Accepted 2025-11-28 06:08:46
Filing Documents
- form6k_112825.htm (6-K) — 11KB
- fy2025ibr.htm (EX-99.1) — 26KB
- fy2025ibr001.jpg (GRAPHIC) — 44KB
- fy2025ibr002.jpg (GRAPHIC) — 44KB
- fy2025ibr003.jpg (GRAPHIC) — 186KB
- fy2025ibr004.jpg (GRAPHIC) — 185KB
- fy2025ibr005.jpg (GRAPHIC) — 173KB
- fy2025ibr006.jpg (GRAPHIC) — 157KB
- fy2025ibr007.jpg (GRAPHIC) — 160KB
- fy2025ibr008.jpg (GRAPHIC) — 198KB
- fy2025ibr009.jpg (GRAPHIC) — 187KB
- fy2025ibr010.jpg (GRAPHIC) — 229KB
- fy2025ibr011.jpg (GRAPHIC) — 159KB
- 0001395064-25-000161.txt ( ) — 2413KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date November 28, 2025 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller